A Study of ZN-c5 in Subjects With Breast Cancer
Public ClinicalTrials.gov record NCT03560531. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
Study identification
- NCT ID
- NCT03560531
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Zeno Alpha Inc.
- Industry
- Enrollment
- 181 participants
Conditions and interventions
Conditions
Interventions
- ZN-c5 Drug
- Palbociclib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2018
- Primary completion
- Apr 25, 2022
- Completion
- Dec 21, 2022
- Last update posted
- Aug 8, 2024
2018 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 3 | Tucson | Arizona | 85719 | — |
| Site 5 | Los Angeles | California | 91010 | — |
| Site 48 | Bethesda | Maryland | 20817 | — |
| Site 47 | St Louis | Missouri | 63110 | — |
| Site 7 | New York | New York | 10029 | — |
| Site 2 | New York | New York | 10032 | — |
| Site 50 | Charleston | South Carolina | 29414 | — |
| Site 4 | Nashville | Tennessee | 37240 | — |
| Site 1 | Houston | Texas | 77030 | — |
| Site 8 | Houston | Texas | 77030 | — |
| Site 6 | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03560531, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 8, 2024 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03560531 live on ClinicalTrials.gov.